Lyudmila Bazhenova

First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results.

D. Ross Camidge, Lyudmila Bazhenova, Ravi Salgia et al. · Journal of Clinical Oncology · 2013 · 80 citations

Cancer Management, Pathology, Metronomic Chemotherapy +19

PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers

Alexander Drilon, Geoffrey R. Oxnard, Lori J. Wirth et al. · Journal of Thoracic Oncology · 2019 · 80 citations · Full text

Phase 1/2, Pl02.08 Registrational Results, Medicine +8

99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation

G.J. Riely, S-H.I. Ou, Igor I. Rybkin et al. · Journal of Thoracic Oncology · 2021 · 80 citations

Medicine, Pharmacology, Pathology +7

Safety and efficacy of brigatinib (AP26113) in advanced malignancies, including ALK+ non–small cell lung cancer (NSCLC).

D. Ross Camidge, Lyudmila Bazhenova, Ravi Salgia et al. · Journal of Clinical Oncology · 2015 · 61 citations

Oncology, Novel Therapy, Medicine +14

1372P Repotrectinib in patients (pts) with NTRK fusion-positive (NTRK+) advanced solid tumors, including NSCLC: Update from the phase I/II TRIDENT-1 trial

Benjamin Solomon, Alexander Drilon, Lyudmila Bazhenova et al. · Annals of Oncology · 2023 · 51 citations · Full text

Solid Tumors, Medicine, Radiopharmaceutical Therapy +7